IPO - Milestone Pharmaceuticals Inc.

Form Type: 424B5

Filing Date: 2025-07-14

Corporate Action: Ipo

Type: New

Accession Number: 000110465925067502

Filing Summary: Milestone Pharmaceuticals Inc. is offering 31,500,000 common shares along with pre-funded warrants to purchase an additional 3,502,335 common shares, and two series of common warrants—Series A and Series B, each for 35,002,335 common shares. The offering price for the common shares is $1.50, and for pre-funded warrants it is $1.499, reflecting the exercise price of the warrants. The Series A warrants expire one year from issuance while the Series B warrants have a five-year expiration. The company is a biopharmaceutical entity focused on developing CARDAMYST (etripamil), a nasal spray aimed at treating paroxysmal supraventricular tachycardia (PSVT). Following FDA's response to a New Drug Application in March 2025, further progress towards marketing approval is underway. The total proceeds from this offering are expected to be around $49.35 million before expenses. Milestone is categorized as a 'smaller reporting company,' indicating compliance with reduced public company reporting requirements. Milestone’s common shares are listed on the Nasdaq under the symbol 'MIST.'

Form Type: 8-K

Filing Date: 2025-07-14

Corporate Action: Ipo

Type: New

Accession Number: 000110465925067579

Filing Summary: Milestone Pharmaceuticals Inc. announced on July 11, 2025, that it has entered into an underwriting agreement with TD Securities (USA) LLC, Piper Sandler & Co., and Wells Fargo Securities, LLC for a public offering of shares. The offering involves 31,500,000 common shares at a price of $1.50 per share, including accompanying Series A and Series B common warrants, and an additional offering of pre-funded warrants. The estimated net proceeds to the company from this offering are approximately $48.7 million after deducting expenses. The offering is set to close on or around July 14, 2025. The securities were offered under a previously declared effective registration statement, and details of the warrants, including their exercise prices and terms related to fundamental transactions, were provided. The company also released press announcements regarding the offering on the same day, which are included in the filing as additional exhibits.